View the latest news and SEC filings
Scroll to
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 18, 2017 |
Registration of depository shares evidenced by American Depository Receipts |
F-6 |
Registration Statements |
|
|
April 18, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 3, 2017 |
Registration statement for certain foreign private issuers |
F-1 |
Registration Statements |
|
|
April 3, 2017 |
CORRESP |
CORRESP |
Other |
|
|
March 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
March 3, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
February 13, 2017 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
January 30, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
